Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 277.90M | 232.34M | 183.03M | 90.09M | 14.56M |
Gross Profit | 181.72M | 163.76M | 124.33M | 54.95M | 7.09M |
EBITDA | 21.87M | -68.50M | -167.31M | -183.34M | -206.19M |
Net Income | -13.62M | -94.01M | -200.38M | -195.82M | -216.08M |
Balance Sheet | |||||
Total Assets | 1.21B | 1.20B | 1.31B | 1.50B | 773.63M |
Cash, Cash Equivalents and Short-Term Investments | 713.72M | 721.14M | 870.12M | 1.22B | 632.42M |
Total Debt | 35.75M | 36.38M | 50.69M | 41.94M | 24.69M |
Total Liabilities | 144.00M | 125.60M | 147.08M | 132.10M | 82.60M |
Stockholders Equity | 1.06B | 1.08B | 1.17B | 1.37B | 681.37M |
Cash Flow | |||||
Free Cash Flow | -8.39M | -137.72M | -304.01M | -260.33M | -90.42M |
Operating Cash Flow | -3.23M | -88.41M | -266.77M | -205.85M | -74.81M |
Investing Cash Flow | 10.80M | -125.45M | 44.84M | -161.10M | -4.53M |
Financing Cash Flow | -12.38M | -21.48M | -24.75M | 821.25M | 686.22M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
72 Outperform | HK$8.59B | 37.25 | 6.49% | ― | 0.87% | -18.05% | |
60 Neutral | HK$1.50B | ― | -1.28% | ― | 17.45% | 85.71% | |
60 Neutral | HK$15.14B | 5.56 | -7.43% | 4.30% | 11.60% | -21.06% | |
51 Neutral | €4.27B | ― | -10.43% | ― | 36.76% | 42.89% | |
50 Neutral | HK$1.16B | ― | -27.82% | ― | -6.12% | 0.43% | |
47 Neutral | HK$2.12B | ― | -2.19% | ― | 5.32% | 89.43% |
Shanghai HeartCare Medical Technology Corp. Ltd. successfully held its 2024 Annual General Meeting (AGM) and Extraordinary General Meeting (EGM) on May 26, 2025, where all proposed resolutions were passed by poll. The meetings were conducted in compliance with the Company Law of the PRC and the Articles of Association, with significant shareholder participation, indicating robust governance and stakeholder engagement.
The most recent analyst rating on (HK:6609) stock is a Buy with a HK$25.60 price target. To see the full list of analyst forecasts on Shanghai Heartcare Medical Technology Corp. Ltd. Class H stock, see the HK:6609 Stock Forecast page.
Shanghai Heartcare Medical Technology Corp. Ltd. has announced an Extraordinary General Meeting (EGM) to be held on May 26, 2025, to discuss and potentially approve the 2025 H Share Incentive Scheme and related resolutions. This initiative is aimed at enhancing shareholder value and aligning the interests of the company’s management with those of its shareholders, potentially impacting its market positioning and stakeholder engagement.
Shanghai HeartCare Medical Technology Corporation Limited has announced a proposal to adopt the 2025 H Share Incentive Scheme. The scheme aims to attract and retain key participants, align their interests with the company’s goals, and enhance long-term performance. The adoption of the scheme is subject to shareholder approval at an upcoming extraordinary general meeting, and it is expected to positively impact the company’s operational and strategic objectives.
Shanghai HeartCare Medical Technology Corporation Limited has announced the closure of its H Share register of members from April 26, 2025, to May 26, 2025, to facilitate its upcoming extraordinary general meeting (EGM) scheduled for May 26, 2025. This closure is aimed at determining the list of shareholders eligible to attend and vote at the EGM, which follows the annual general meeting on the same day. The move is significant for stakeholders as it outlines the procedural steps for shareholder participation and voting, ensuring transparency and orderly conduct of corporate governance.
Shanghai Heartcare Medical Technology Corp. Ltd. has announced its 2024 Annual General Meeting (AGM) scheduled for May 26, 2025. During the AGM, the company will consider and approve various resolutions, including the work reports of the board and supervisory committee, profit distribution plan, audited financial statements, and the re-appointment of auditors. Additionally, a special resolution will be discussed to authorize the issuance of additional shares, granting the board a general mandate to manage such issuances. These resolutions are pivotal for the company’s strategic planning and financial management, potentially impacting its market position and shareholder value.